miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

D-Wave (QBTS) Q2 2025 Earnings Call Transcript

View original at finance.yahoo.com
D-Wave (QBTS) Q2 2025 Earnings Call Transcript Image source: The Motley Fool. DATE Thursday, August 7, 2025 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Alan E…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • D-Wave has the opportunity to be the first independent publicly held quantum computing company to achieve sustained profitability

    80% confidence
  • Characterizing annealing quantum computing as niche is misleading and ill-informed

    80% confidence
  • M&A is now a strategic priority with goal to announce acquisitions in 2025

    80% confidence
  • Quarterly non-GAAP OpEx will be approximately 15% higher than Q2 actual for remainder of 2025

    80% confidence
  • Gate model quantum computers cannot universally solve all problems better than classical computers

    80% confidence
  • DARPA made a huge mistake by excluding annealing from the QBI program

    80% confidence
  • Peer-reviewed research shows annealing quantum computers outperform and will continue to outperform gate model on optimization problems

    80% confidence
  • D-Wave was the first to achieve quantum supremacy on a useful real-world problem

    80% confidence

Data points we hold from this source

D-Wave Quantum Inc. · gross profit non gaap1.6 million_USD
D-Wave Quantum Inc. · retention rate90 percent
D-Wave Quantum Inc. · revenue2.2 million_USD
D-Wave Quantum Inc. · gross profit gaap2.0 million_USD
D-Wave Quantum Inc. · analyst coverage10 analysts
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com